Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM)

Trial Objective

The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.

Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM)

Sirolimus is approved by the United States Food and Drug Administration (FDA) for the treatment of LAM. A recent trial showed that sirolimus stabilized lung function in patients with moderate and severe disease. Our researchers want to find out if giving low-dose sirolimus earlier in the course of treatment safely and effectively prevents further lung damage from LAM.


This trial is active and currently recruiting.

How to Participate

For more information, contact Jamie Henriksen at 303.398.1233 or complete the form below.

Who Can Participate

Adults who have been diagnosed with lymphangioleiomyomatosis are eligible to participate. 

Estimated Time Commitment

2 years

The study will last for two years and involve seven visits and one phone call, as well as a remote blood draw. Total time commitment is about 9 hours.

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

National Institutes of Health (NIH)




Any Gender

Principal Investigators

Request More Information